QPPV.COM KNOWLEDGE ASSESSMENT

Knowledge Assessment: GVP Module X — Additional Monitoring of Medicinal Products

Test your understanding of the concepts covered by GVP Module X: Additional Monitoring of Medicinal Products.

Question 1 of 10Pass mark: 80%

Question 1 of 10 Which activity would be the weakest measure of the effectiveness of an additional-monitoring system if considered alone?

Assessing whether relevant reports reach case processing and signal management Evaluating whether information contributes to improved understanding of the safety profile Counting the number of promotional or reporting-awareness activities conducted Checking whether status changes are accurately reflected in controlled product information

Question 2 of 10 What should an inspection primarily assess beyond whether the black triangle appears on a package?

Whether the product has generated a predetermined number of reports Whether the status is controlled and whether resulting safety information is integrated into processing, signal detection and aggregate evaluation Whether every reported event has been proven causal before submission Whether the product has a higher adverse-reaction rate than every non-monitored medicine

Question 3 of 10 What is the primary purpose of EU additional monitoring?

To identify medicines whose benefit-risk balance is considered negative To strengthen collection and visibility of post-authorisation safety information for selected medicines To exempt selected medicines from routine pharmacovigilance requirements To restrict prescribing until a medicine has accumulated sufficient real-world evidence

Question 4 of 10 A product leaves the additional-monitoring list. What does this change mean?

All pharmacovigilance surveillance for the product should stop The product has been demonstrated to be free of important risks The product no longer meets the applicable criteria or its status has otherwise changed, while routine pharmacovigilance continues All previously received adverse-reaction reports should be removed from the safety database

Question 5 of 10 Which control would best demonstrate that an MAH manages additional-monitoring status as controlled regulatory information?

Allowing each affiliate to decide independently whether to display the symbol Maintaining reconciliation between the current regulatory status, approved product information and implemented local materials Measuring only how many packages display the symbol at headquarters Delegating all status decisions to the artwork vendor without regulatory oversight

Question 6 of 10 Which product-information approach is consistent with the EU additional-monitoring framework?

Include the inverted black triangle together with the standard explanatory reporting statement Include the triangle without any accompanying explanation to avoid alarming patients Include a statement that the product is proven to be high risk Include the symbol only in internal pharmacovigilance documents

Question 7 of 10 Which type of information illustrates why the quality of an individual spontaneous report matters?

Only the total number of reports received during the quarter The product's sales revenue without any clinical details Clinical chronology, concomitant medicines, patient characteristics and outcome The presence of the black triangle on the package

Question 8 of 10 Which interpretation of an increase in spontaneous reports after introduction of a black triangle is scientifically most appropriate?

It proves that the medicine's underlying risk has increased It proves that the medicine is being used outside its authorised indication It may reflect increased awareness and reporting, so the trend requires assessment using clinical and exposure-related evidence It should be disregarded because reports generated after additional monitoring are inherently biased

Question 9 of 10 Which statement best distinguishes additional monitoring from an RMP?

Additional monitoring and the RMP are interchangeable names for the same regulatory activity The RMP describes risks, missing information and related activities, whereas additional monitoring is a status that strengthens reporting and safety-information collection Additional monitoring replaces the RMP for products containing new active substances An RMP is concerned only with reporting, whereas additional monitoring covers only risk minimisation

Question 10 of 10 Why should literature and other non-spontaneous data sources continue to be monitored for an additionally monitored product?

Because the black triangle limits surveillance to literature rather than spontaneous reports Because additional monitoring increases reporting emphasis but does not narrow the evidence base used for signal and aggregate safety assessment Because spontaneous reports for additionally monitored products cannot be assessed scientifically Because literature evidence automatically determines whether the product must be withdrawn

Knowledge Assessment: GVP Module X — Additional Monitoring of Medicinal Products

Cookie Settings